{"schema":"sb.node.v1","id":"sb:e/0346413501cf19e803459176","kind":"entity","label":{"text":"phase iib","locale":"en"},"identity":{"anchor":"label:en:phase iib","strength":"label"},"asOf":{"knowledgeCutoff":"2026-10-15T21:55:31.406490+00:00","snapshot":"deploy a770869106686dde6b625f65594d61875f81a906"},"lens":{"kind":"public"},"build":{"plane":"projected","builtFrom":["entity_graph.slim.json","entity_receipts (deploy asset)","event_graph.json","truth_records (deploy asset)","corroborated_record.json"],"rule":"node-projection.entity@v1"},"standing":{"evidence":{"supporting":28,"separatePublishers":10,"basis":"documents that mention the subject and the outlets that carried them; a mention is evidence the referent is in use, not evidence about any claim","receiptsOnTopic":{"state":"measured","share":0.5,"named":14,"of":28,"basis":"documents whose own title or summary lead names the subject, over every counted document that mentions it anywhere (the entity graph's measurement); receipts are drawn from the former only"}},"admission":{"state":"canonical","kind":"cannot-measure","kindBasis":"graph-predates-admission-kinds","reason":"entity graph provenance 'curated'; the entity graph was built before it carried admission kinds","policy":"promotion (admission kind not carried)"},"disposition":{"state":"served","reason":"public record"},"validity":{"from":"2026-09-21","to":"2026-10-13","basis":"first and last day we saw it mentioned; not the subject's own lifetime"},"measurement":{"state":"partial","blind":["assertion coverage 0.179: about 82% of mentions carry no typed assertion"]}},"dimensions":{"domains":["fda_decisions"],"activeDays":15,"assertions":{}},"up":[],"upNote":"An entity is a root: it is contained by nothing. Pan out by following R.","children":{"count":11,"byKind":{"observation":11},"items":[{"id":"sb:o/ae7e053b6d2ac7d04cf72c04","kind":"observation","label":"Clinical Trials Arena · 2026-10-13 · Tortugas’ Phase IIb schizophrenia trial of obuprazine meets primary endpoint","url":"https://www.clinicaltrialsarena.com/news/tortugas-schizophrenia-trial-meets-endpoint/"},{"id":"sb:o/e199a092a7e2f567e0711131","kind":"observation","label":"Clinical Trials Arena · 2026-10-09 · Endeavor’s Phase IIb IPF study of taladegib meets endpoints","url":"https://www.clinicaltrialsarena.com/news/endeavors-taladegib-study-meets-endpoints/"},{"id":"sb:o/110d973290e22533b3a164cc","kind":"observation","label":"Clinical Trials Arena · 2026-10-08 · MimiVax announces disappointing pivotal Phase IIb trial data for cancer vaccine","url":"https://www.clinicaltrialsarena.com/analyst-comment/mimivax-announces-disappointing-pivotal-phase-iib-trial-data-for-cancer-vaccine/"},{"id":"sb:o/c707222fecba40230365b2b1","kind":"observation","label":"AllSci News · 2026-10-07 · SurVaxM misses Phase IIb glioblastoma survival endpoint but shows benefit in younger patients","url":"https://allsci.com/news/clinical-trials/survaxm-glioblastoma-misses-primary-endpoint-in/"},{"id":"sb:o/c9f75a3d2d2872886d703e48","kind":"observation","label":"Clinical Trials Arena · 2026-10-01 · R1 Therapeutics secures $80.5m to fund Phase IIb AP306 study","url":"https://www.clinicaltrialsarena.com/news/r1-therapeutics-80m-fund-ap306-study/"},{"id":"sb:o/92a4ed3305969bdae15630fd","kind":"observation","label":"AllSci News · 2026-10-01 · R1 Therapeutics expands Series A to USD 80.5m as AP306 nears Phase IIb readout","url":"https://allsci.com/news/biotech/therapeutics-expands-series-r1-to-805-million-to/"},{"id":"sb:o/b325be62c27d98d00fa5af81","kind":"observation","label":"Clinical Trials Arena · 2026-10-01 · MSD’s Phase IIb study of tulisokibart achieves primary endpoint","url":"https://www.clinicaltrialsarena.com/news/msds-tulisokibart-achieves-primary-endpoint/"},{"id":"sb:o/6e13224b3995fda083c684ed","kind":"observation","label":"AllSci News · 2026-10-01 · Lilly's EloraTZP combination tops tirzepatide alone in Phase IIb obesity and diabetes trial","url":"https://allsci.com/news/clinical-trials/eloratzp-obesity-diabetes-trial-lillys/"},{"id":"sb:o/edabeb93d8f3098d5ea7948d","kind":"observation","label":"Clinical Trials Arena · 2026-09-23 · Vertex reports results from Phase IIb AMPLIFIED trial for AMKD","url":"https://www.clinicaltrialsarena.com/news/vertex-amplified-trial-results-amkd/"},{"id":"sb:o/b475af34f62be7b70a82b5e7","kind":"observation","label":"Clinical Trials Arena · 2026-09-21 · First patient dosed in Accro Bioscience’s Phase IIb AC-101 study","url":"https://www.clinicaltrialsarena.com/news/first-patient-dosed-accro-biosciences-ac-101-study/"}],"cursor":"c1.eyJpZCI6InNiOmUvMDM0NjQxMzUwMWNmMTllODAzNDU5MTc2IiwibCI6ImNoaWxkcmVuIiwibyI6MTAsImsiOm51bGwsImEiOiIyMDI2LTEwLTE1VDIxOjU1OjMxLjQwNjQ5MCswMDowMCJ9","order":"newest first; we keep the 11 newest receipts for this entity whose own title or summary lead (the entity graph's test) names it. Its other observations are counted in standing.evidence.supporting but are not addressable in v1"},"relations":{"count":2,"byKind":{"co-mentioned":2},"items":[{"kind":"relation","label":"co-mentioned with adverse events (12 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/cc96b7798d18486c600b6a2b"},{"kind":"relation","label":"co-mentioned with clinical trials (9 documents)","role":"co-mentioned","relationKind":"co-mentioned","members":2,"id":"sb:r/d24d0ec061edb49dfdab6876"}],"cursor":null,"order":"situations first, then claims (the subject's own maintained record, then site-wide corroborated clusters; each label ends with its standing), then co-mentions by shared documents, descending. Co-mentions are the ten strongest the entity graph keeps per entity"},"edge":{"state":"continues"},"links":{"rest":"/api/v1/node/e/0346413501cf19e803459176","mcp":"traverse {\"id\":\"sb:e/0346413501cf19e803459176\"}","page":"/entity/phase-iib/"},"limits":{"levelsPerCall":1,"pageSize":10,"maxPageSize":50,"membersMax":50,"statement":"One level per call: depth is 1 and only 1, and there is no whole-graph dump. pageSize 1-50 (default 10); a page limit is a cursor, never an edge. Members are listed up to 50. At most 60 traverse calls a minute per caller (runaway-loop protection, not a meter). One knowledge cutoff is served: the deploy's."},"actions":[{"verb":"unfold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/0346413501cf19e803459176\",\"level\":\"children\"}"},{"verb":"fold","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/0346413501cf19e803459176\"}"},{"verb":"panOut","lit":false,"effect":"read","layer":"free-record","reason":"An entity is a root: it is contained by nothing. Pan out by following R."},{"verb":"follow","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/0346413501cf19e803459176\",\"level\":\"relations\"}"},{"verb":"receipts","lit":false,"effect":"read","layer":"free-record","reason":"receipts are the observations below this node; unfold to reach them"},{"verb":"edge","lit":true,"effect":"read","layer":"free-record","call":"traverse {\"id\":\"sb:e/0346413501cf19e803459176\"}"},{"verb":"asOf","lit":false,"effect":"read","layer":"free-record","reason":"v1 serves one knowledge cutoff, this deploy's; walking an earlier cutoff needs retained history, which v1 does not keep"},{"verb":"switchObserver","lit":false,"effect":"read","layer":"free-record","reason":"the public record is the same for every observer; traversal through a Watch's lens is not served in v1"},{"verb":"readOriginal","lit":false,"effect":"read","layer":"free-record","reason":"no translation is applied on this node; every label is the source's own text"},{"verb":"save","lit":false,"effect":"watch-declaration","layer":"watch","reason":"saving applies to a configured Watch; configure one around this node first (free), then save it"},{"verb":"deliver","lit":false,"effect":"watch-declaration","layer":"watch","reason":"delivery applies to a saved Watch"},{"verb":"format","lit":false,"effect":"watch-declaration","layer":"watch","reason":"output format applies to a saved Watch"},{"verb":"deltaR","lit":false,"effect":"read","layer":"watch","reason":"Delta R needs a saved Watch with a previous reading"},{"verb":"read","lit":false,"effect":"read","layer":"one-time-read","reason":"one-time Reads are not offered through this door; use ask"}]}